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Background: It is not well established whether the increased number of leukocytes in the seminal fluid impairs the
outcomes of assisted reproductive technology (ART). This investigation analysed the outcomes of the
intracytoplasmic sperm injection (ICSI) and intracytoplasmic morphologically selected sperm injection (IMSI) cycles
in couples in which the male partner exhibited leukocytospermia.
Methods: A total of 100 cycles in 100 couples were included in this study. For the ICSI or IMSI procedures, the
patients were divided into two groups according to the presence or absence of leukocytospermia and then
matched by (female) age:
– ICSI: Group I (n= 25): Leukocytospermia - semen samples with a leukocyte count of greater than or equal to
1× 10(6)/mL; and Group II (n = 25): Non-leukocytospermia - semen samples with a leukocyte count< 1× 10(6)/
mL.
– IMSI: Group I (n = 25): Leukocytospermia; and Group II (n = 25): Non-leukocytospermia.
The endpoints included the rates of fertilisation, implantation, clinical pregnancy, miscarriage, ongoing pregnancy
and live birth. Student’s t-tests, Mann–Whitney tests and Chi-square tests were performed, and P< 0.05 was
considered significant.
Results: The data from the ICSI groups showed that leukocytospermia did not have a negative influence on the
rates of fertilisation (Group I: 57.9+/−30.2%, Group II: 61.9+/−27.7%; P= 0.74), implantation (Group I: 12.3%; Group II:
13.5%; P= 0.93), clinical pregnancy (Group I: 24%; Group II: 24%; P= 1.0), miscarriage (Group I: 0, Group II: 0), ongoing
pregnancy (Group I: 24%; Group II: 24%; P= 1.0), or live births (Group I: 24%; Group II: 24%; P= 1.0). Similarly, the
data from the IMSI groups also showed that the leukocytospermia did not have a negative influence on the rates
of fertilisation (Group I: 67.6+/−24.6%, Group II: 59.5+/−28.1%; P= 0.36), implantation (Group I: 17.5%; Group II: 16.7%;
P= 0.90), clinical pregnancy (Group I: 28%; Group II: 24%; P= 1.0), miscarriage (Group I: 14.3%; Group II: 0; P= 0.33),
ongoing pregnancy (Group I: 24%; Group II: 24%; P= 1.0), or live births (Group I: 24%, 6/25; Group II: 24%, 6/25;
P= 1.0).
Conclusions: The results indicate that the leukocytospermia may not have a negative effect on the outcomes of
ICSI or IMSI cycles. Nevertheless, it seems that it is necessary to more precisely determine the effects, if any, of
seminal leukocytes on fertilisation and implantation processes. Such efforts will help to establish a more reliable
leukocyte threshold, which could eventually demonstrate whether there is a negative influence on the ART
procedures.
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Male infertility represents an important etiological factor
for infertile couples to consider, and semen analysis is the
main screening tool that guides diagnosis. Among the
parameters evaluated in the seminal analyses, the white
blood cell count is considered, as are sperm concentration,
motility and morphology. According to the World Health
Organization (WHO), a leukocyte count ≥1× 106/mL in a
semen sample is indicative of leukocytospermia [1]. An
elevated leukocytes count is found in the seminal fluid of
approximately 30% of infertile men, even in the absence of
inflammatory symptoms or a seminal bacterial infection
[2]. Reports on the influence of leukocytospermia on male
fertility are contradictory [3-5]. Nevertheless, there is evi-
dence indicating that leukocytospermia has a negative im-
pact on semen quality due to the production of reactive
oxygen species (ROS) [6-8]. Although there is ongoing
controversy concerning the effects of leukocytospermia on
the integrity of sperm DNA [9], it was recently reported
that semen samples with leukocytospermia are more likely
to evidence sperm with DNA fragmentation [10,11]. How-
ever, few reports have analysed the influence of leukocy-
tospermia on the outcomes of assisted reproductive
technology (ART) [12-17].
Some authors have demonstrated the influence of leu-
kocytospermia on in vitro fertilization (IVF)/ intracyto-
plasmic sperm injection (ICSI) outcomes. Using
multivariate analysis of the semen parameters in 195
couples undergoing in vitro fertilisation, Talbert et al.
[12] observed that semen parameters correlating most
closely with the reduced ability to fertilise mature
oocytes included two primary factors, including a slow
rate of forward progression of sperm and the presence
of excess numbers of white cells in the semen. Krausz
et al. [13] investigated the influence of two factors, in-
cluding ROS generated by the human spermatozoa and
contaminating leukocytes, on sperm movement and
in vitro fertilisation. The authors showed that the pres-
ence of leukocytes was associated with elevated levels of
spontaneous ROS production, impaired movement, and
a reduced capacity for in vitro fertilisation. Sukcharoen
et al. [14] placed a particular emphasis on the degree of
leukocyte contamination as a criterion that accurately
predicts the fertilising potential of human sperm suspen-
sions in vitro. The results of the study of Yilmaz et al.
[15] indicated that some semen parameters and the out-
come of ICSI were negatively affected by the presence of
leucocytospermia. Conversely, other authors have ques-
tioned the influence of these leukocytes on the results of
ART. Lackner et al. [16] found that leukocytospermia
has no negative influence on fertilisation or pregnancy
rates following either IVF or ICSI; however, one limiting
factor of this study was the small number of leukocytos-
permic semen samples in both the IVF and ICSI groups.Barraud-Lange et al. [17] observed that, at moderate
levels (<106/mL), leukocytospermia appears to be within
the physiologic range. It is associated with an improved
capacity for sperm fertilisation and pregnancy outcomes.
At higher concentrations, however, leukocytospermia
alters neither sperm fertilisation ability nor the probabil-
ity of clinical pregnancy, compared with nonleukocytic
patients with infertility. However, in the latter case, the
pregnancy rate was reduced.
Innovative ART methods developed for the selection
of sperm have provided new insight into the interaction
between the sperm quality and clinical results [18,19].
To test the hypothesis that subtle sperm organelle mal-
formations are associated with ART results, Bartoov
et al. [20,21] developed a method of evaluating human
spermatozoa in real time at a high magnification
(≥ 6000x), which is called motile sperm organelle
morphology examination (MSOME). This method pro-
moted the development of the intracytoplasmic morpho-
logically selected sperm injection (IMSI) technique.
IMSI is based on sperm normality, as defined by the
MSOME classifications, and it is aimed at improving the
conventional ICSI outcomes by focusing on the relation
between the sperm morphological abnormalities observ-
able at high magnification and related DNA damage
[21-25]. Various studies have demonstrated that IMSI
significantly improves embryo quality [21,26], the rate of
development up to the blastocyst stage [27,28], the rates
of implantation and pregnancy after embryo transfer on
days 2 or 3 [21,22,26,29-31] or during the blastocyst
stage [28], as well as the likelihood of having a normal,
healthy child [32]. IMSI also appears to significantly de-
crease miscarriage rates [21,22,28,30]. Considering that
ROS production, which is potentially associated with the
presence of leukocytes in the semen, has been correlated
with increased sperm DNA fragmentation [7,9,33], it is
plausible that the use of IMSI may benefit the clinical
outcomes of patients with leukocytospermia. These
benefits would be based on the potential to exclude
morphological sperm abnormalities that are potentially
related to DNA damage. However, the repercussions of
the clinical use of IMSI in patients with leukocytospermia
have not yet been determined.
Therefore, this study was designed to assess the effect
of leukocytospermia on the clinical outcomes (e.g., the
rates of fertilisation, implantation, pregnancy, miscar-
riage, ongoing pregnancy and live births) associated with
ICSI and IMSI.Methods
Study participants
A total of 100 couples who were enrolled in the IVF/
ICSI programme of the Centre for Human Reproduction
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treatment were included in this study.
The couples were referred for either the ICSI or the
IMSI procedures.The ICSI procedure
The patients were divided into two groups according to
the presence or absence of the leukocytospermia based
on the seminal evaluations and matched by (female)
ages: Group I (study, n = 25): Leukocytospermia semen
samples with a leukocyte count ≥1 × 106/mL; and Group
II (control, n = 25): Non-leukocytospermia semen sam-
ples with a leukocyte count <1 × 106/mL.The IMSI procedure
The patients were divided into two groups according to
the presence or absence of leukocytospermia based on
the seminal evaluations and matched by (female) ages:
Group I (study, n = 25): Leukocytospermia semen sam-
ples with a leukocyte count ≥1 × 106/mL; and Group II
(control, n = 25): Non-leukocytospermia semen samples
with a leukocyte count <1 × 106/mL.
All of the couples who enrolled in the study met the
following inclusion criteria: subfertility with a need for
assisted reproduction with ejaculated spermatozoa, no
previous ART attempts, a maternal age ≤ 39 years, a nor-
mal karyotype in both partners and a lack of uterine
defects, ultrasonographic evidence of hydrosalpinx,
infections, endocrine problems, coagulation defects or
thrombophilia and autoimmune defects (including the
presence of anti-phospholipid antibodies). The microbio-
logical analyses of the semen were conducted during
routine semen evaluations. Bacterial examinations of the
semen were not carried out on the same day as the IMSI
or ICSI procedures. The group assignments to the ICSI
or IMSI procedures was performed by serial entry, with
alternate allocations per set of two treatment cycles (i.e.,
two allotted to the ICSI procedure then two allotted to
the IMSI procedure). The division between the groups
was performed as follows: after the referral of a couple
whose male partner had leukocytospermia for ICSI or
IMSI, the following couple with the same characteristics
(i.e., of same age (± 1 year) and fulfilled the inclusion
criteria) whose male partner did not have leukocytosper-
mia was referred for either ICSI or IMSI, respectively. In
total, 150 couples were screened for this study. The 50
couples whose male partners exhibited no leukocytos-
permia were not included because they did not share the
same characteristics of the couples with leukocytosper-
mia included immediately prior to their assessments.
Written informed consents were obtained from all cou-
ples, and this study was approved by an internal institu-
tional review board.Ovarian stimulation and oocyte recovery culture protocol
All of the patients were submitted to the same protocol
of controlled ovarian stimulation. First, the extent of
pituitary downregulation was established with leuprolide
acetate at a dose of 1 mg/day (Lupron; Abbott, Brazil),
which was started during the luteal phase of the previous
cycle. After 14 days of treatment with the GnRH analogue
and after a confirmation of a pituitary downregulation, the
administration of recombinant FSH (Gonal-FW; Serono
Barueri, SP, Brazil) was initiated at a dose of 150–225 IU
(with doses dependent on the patient’s age) and 75 IU/day
of recombinant LH (LuverisW, Serono, SP, Brazil) for a
period of 7 days. When one or more follicles measuring
≥17 mm were observed, recombinant HCG (OvidrelW;
Serono, Brazil) was administered at a dose of 250 μg, and
oocyte retrieval was scheduled 35–36 hours later.
Semen preparation
Semen samples were collected in sterile containers via
masturbation after a sexual abstinence period of 2 to
5 days. The liquefied, fresh semen samples were pre-
pared using an ISolate discontinuous concentration gra-
dient (Irvine Scientific, Santa Ana, CA, USA). The final
semen pellet was resuspended in 0.2 mL of modified
HTF medium (Irvine Scientific, Santa Ana, CA, USA)
supplemented with 10% human serum albumin (Irvine
Scientific, Santa Ana, CA, USA).
Each original/fresh semen sample was analysed for the
standard semen quality parameters according to the
WHO guidelines [1]. An observation of the presence or
absence of leukocytospermia, which was defined as the
presence of ≥1 × 106/mL of white blood cells, was carried
out at this point. Sperm morphology was analysed
according to the MSOME criteria when the couple
underwent the IMSI procedure [20].
ICSI procedure
A conventional ICSI was performed using a Nikon
Eclipse TE 300 inverted microscope, equipped with the
Narishige 231 D-2 remote-controlled hydraulic micro-
manipulators (Narishige, Tokyo, Japan) and the Nar-
ishige IM-9B injectors. Spermatozoa were selected at
400x magnification using a Hoffman modulation con-
trast based on a set of published guidelines.
IMSI procedure
A 1-μL aliquot of sperm cell suspension was transferred
to a 5-μL microdroplet of modified HTF medium
that contained 7% polyvinylpyrrolidone solution (PVP
medium; Irvine Scientific, USA). The microdroplet was
placed into a sterile glass dish (FluoroDishTM; World Pre-
cision Instruments, USA) in sterile paraffin oil (Ovoil-100;
Vitrolife, Goteborg, Sweden). Sperm cells that were sus-
pended within the microdroplet were placed on a
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jective lens that was previously covered by a droplet of
immersion oil. In this manner, the suspended motile
sperm cells in the observation droplet could be examined
at a high magnification through an inverted microscope
(Eclipse TE 2000 U; Nikon, Japan) equipped with high-
powered differential interference contrast optics (DIC/
Nomarski). Images were captured using a colour video
camera that contained effective picture elements (pixels)
for the production of high-quality images, and these
images were projected onto a colour video monitor. The
morphological evaluation was accomplished using a moni-
tor screen, and the total calculated magnification was
8400x (total magnification: objective magnification= 100x,
magnification selector = 1.0x, video coupler magnifica-
tion= 1.0x and calculated video magnification= 84.50x).
The spermatozoon used for IMSI was classified as
morphologically normal if it exhibited a normal nucleus,
an acrosome, a post-acrosomal lamina, a neck and a tail,
and did not present a cytoplasmic droplet or cytoplasm
around the head [20]. The subcellular organelles
were morphologically classified based on the presence of
specific malformations. These malformations were
defined according to the subjective descriptive approach
reported by Bartoov et al. [20] based on studies utilising
transmission and scanning electron microscopy. Accord-
ing to results obtained using transmission electron mi-
croscopy [20], a morphologically normal state of the
nucleus was defined by the shape and content of the
chromatin. The criterion for normality of the nuclear
form was a smooth, symmetrical and oval configuration.
The normal means for the length and width were esti-
mated as 4.75 ± 2.8 and 3.28 ± 0.20 μm [20], respectively,
and the form was classified as abnormal when it pre-
sented a variation of ±2 standard deviations on one of
its axes (length: ≥5.31 or ≤4.19 μm; width: >3.7 or
<2.9 μm). For a rapid evaluation of the nuclear form, a
fixed, transparent, celluloid form of a sperm nucleus fit-
ting the criteria was superimposed on the examined cell
(chablon construction based on ASTM E 1951-2 [34]).
In the same manner, the nuclear form was considered
abnormal if an extrusion or invagination of the nuclear
chromatin mass was detected (i.e., a regional malforma-
tion of the nuclear form). The chromatin content was
considered abnormal if one or more vacuoles occupied
more than 4% of the nuclear area (if necessary, visual
evaluation was aided by superimposing a celluloid form
of a large vacuole on the examined cell). A nucleus was
considered normal if both the nuclear form and chroma-
tin content were normal.
The same technician performed all sperm selections,
and only normal spermatozoa were injected in this
study. The time involved in the selection step was 30–
60 min/sample, and at least three spermatozoids wereselected for each MII oocyte. After the sperm selection
process, the IMSI microinjections were conducted in the
same manner as for the ICSI injections. The spermato-
zoids were still motile when captured for the final
selection.
Oocyte and embryo culture and transfer
The sperm-injected oocytes, zygotes and embryos from
both of the IMSI (Leukocytospermia and Non- leukocy-
tospermia) and ICSI (Leukocytospermia and Non-
leukocytospermia) groups were subjected to the same
culture conditions. On day 2, the two to three best-
scoring embryos from both of the ICSI (Leukocytospermia
and Non-leukocytospermia) and IMSI (Leukocytospermia
and Non-leukocytospermia) groups were transferred. The
quality of the transferred embryos was similar among the
four groups.
Statistical analysis
The data were analysed using InStat version 3.0 (Graph-
Pad Software, San Diego, California, USA) on a Macin-
tosh computer (Apple Computer Inc., Cupertino,
California, USA). The endpoints of the investigation
included the rates of fertilisation, implantation, clinical
pregnancy, miscarriage, ongoing pregnancy and live
births. Fertilisation was defined as zygotes containing
two pronuclei after the ICSI or IMSI procedures. A
pregnancy was defined as the presence of a gestational
sac with a heartbeat that was visualised by ultrasound
4–6 weeks after embryo transfer. A miscarriage was
defined as the termination of the pregnancy up to
20 weeks of gestation. When appropriate, Student’s t-tests,
Mann–Whitney tests and Chi-squared tests were utilised,
and P< 0.05 was considered significant.
Results
The distributions of the main characteristics of the cycle
observed for the ICSI and IMSI procedures were equal
(P> 0.05). These data are summarised in Table 1.
ICSI procedure
Whereas there seems to be an association between an
increased number of leukocytes and a decreased quality
of semen samples, our data showed that leukocytosper-
mia did not have a negative influence on the fertilisation
rate (Group I: 57.9 ± 30.2%, Group II: 61.9 ± 27.7%;
P= 0.74), implantation rate (Group I: 12.3%, 7/54; Group
II: 13.5%, 7/52; P= 0.93), clinical pregnancy rate per
cycle (Group I: 24%, 6/25; Group II: 24%, 6/25; P= 1.0),
miscarriage rate (Group I: 0, Group II: 0), ongoing preg-
nancy rate (Group I: 24%, 6/25; Group II: 24%, 6/25;
P= 1.0), or live birth per cycle (Group I: 24%, 6/25;
Group II: 24%, 6/25; P= 1.0) after ICSI. The results and
characteristics of the patients are shown in Table 2.
Table 1 Comparison between the ICSI and IMSI procedures
Total P Leukocytospermia P Non-leukocytospermia P
ICSI IMSI ICSI IMSI ICSI IMSI
Cycles 50 50 25 25 25 25
Leukocytes in semen
(x106)(mean± SD)
1.5 ± 1.8 (0–8) 2.5 ± 7.5 (0–50) 0.41 2.4 ± 1.7 (1–8) 4.8 ± 10.5(1–50) 0.10 0.4 ± 0.3 (0–0.8) 0.4 ± 0.3 (0–0.8) 0.76
Female age (years) 34.4 ± 3.6 34.8 ± 3.9 0.67 34.4 ± 3.8 34.8 ± 4.1 0.75 34.5 ± 3.6 34.8 ± 3.8 0.79
Male age (years) 36.9 ± 5.0 37.2 ± 5.6 0.80 37.2 ± 5.0 37.4 ± 5.2 0.91 36.7 ± 5.0 37.0 ± 6.0 0.81
Aetiology (%) 0.10 0.43 0.26
Male 48% (24/50) 40% (20/50) 56% (14/25) 36% (9/25) 40% (10/25) 44% (11/25)
Idiopathic 16% (8/50) 24% (12/50) 16% (4/25) 20% (5/25) 16% (4/25) 28% (7/25)
Tuboperitoneal 10% (5/50) 16% (8/50) 12% (3/25) 24% (6/25) 8% (2/25) 8% (2/25)
Endometriosis 18% (9/50) 8% (4/50) 8% (2/25) 4% (1/25) 28% (7/25) 12% (3/25)
Tuboperitoneal + endometriosis 6% (3/50) —— 4% (1/25) —— 8% (2/25) —
Male + tuboperitoneal 2% (1/50) 8% (4/50) 4% (1/25) 8% (2/25) —— 8% (2/25)
Male + t endometriosis —— 4% (2/50) —— 8% (2/25) —
Semen parametersa (mean± SD)
Total sperm count (x106/mL) 56.5 ± 49.5 50.9 ± 40.3 0.87 43.2 ± 44.5 41.0 ± 34.8 0.70 69.7 ± 51.5 60.8 ± 43.6 0.58
Motility (% spermatozoa)
-rapid + slow\progression 43.1 ± 19.7 51.4 ± 22.2 0.09 35.8 ± 17.8 44.3 ± 21.8 0.17 50.7 ±17.9 58.6 ± 20.8 0.22
-non-progressive 11.5 ± 11.4 9.6 ± 11.2 0.08 11.9 ± 12.3 10.5 ± 13.7 0.17 11.2 ± 10.3 8.6 ± 8.3 0.25
-immotile 42.6 ± 20.6 38.6 ± 20.4 0.42 50.4 ± 23.6 45.8 ± 21.0 0.50 35.9 ± 13.6 31.4 ± 17.3 0.36
Morphology
-normal forms (%) 14 ± 10.5 —— 10.1 ± 0.8 —— 17.9 ± 20.3 ——
Vitality (%) 46.9 ± 19.2 44.2 ± 19.6 0.66 45.1 ± 17.5 43.1 ± 20.5 0.81 48.8 ± 20.9 45.3 ± 18.7 0.52
MSOME b (%)
-normal spermatozoa —— 1.13 ± 1.65 —— 0.92 ± 1.43 —— 1.35 ± 1.87
-spermatozoa with vacuoles
occupying >50% of the nuclear area
—— 35.9 ± 23.05 —— 37.8 ± 20.2 34.0 ± 25.9
Metaphase II oocytes (n) 7.8 ± 4.3 7.8 ± 5.2 0.69 8.5 ± 4.2 8.2 ± 5.7 0.66 7.3 ± 4.2 7.4 ± 4.9 0.81
Fertilisation rate (%) 59.9 ± 28.7 63.5 ± 26.5 0.55 57.9 ± 30.2 67.6 ± 24.6 0.35 61.9 ± 27.7 59.5 ± 28.1 0.86
Embryos transfer (n) 2.1 ± 0.9 2.4 ± 0.8 0.21 2.2 ± 0.9 2.3 ± 0.8 0.90 2.1 ± 1.0 2.6 ± 0.9 0.10
Implantation rate (%) 13.2% (14/106) 17.2% (19/111) 0.54 12.3% (7/54) 17.5% (10/57) 0.68 13.5% (7/52) 16.7% (9/54) 0.84
Pregnancy/cycle (%) 24% (12/50) 26% (13/50) 0.81 24% (6/25) 28% (7/25) 0.74 24% (6/25) 24% (6/25) 1
Miscarriage (%) 0 7.7% (1/13) 0.32 0 14.3% (1/7) 0.33 0 0 ——
Ongoing pregnancy/cycle (%) 24% (12/50) 24% (12/50) 1 24% (6/25) 24% (6/25) 1 24% (6/25) 24% (6/25) 1
Live birth/cycle (%) 24% (12/50) 24% (12/50) 1 24% (6/25) 24% (6/25) 1 24% (6/25) 24% (6/25) 1
a Semen quality parameters according to the World Health Organization [1]; and b motile sperm organelle morphology examination.
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Similar to our ICSI results, we identified an association
between an increased number of leukocytes and decreased
quality of semen samples. However, our data showed that
leukocytospermia did not have a negative influence on the
fertilisation rate (Group I: 67.6± 24.6%, Group II:
59.5± 28.1%; P= 0.36), implantation rate (Group I: 17.5%,
10/57; Group II: 16.7%, 9/54; P=0.90), clinical pregnancy
rate per cycle (Group I: 28%, 7/25; Group II: 24%, 6/25;
P=1.0), miscarriage rate (Group I: 14.3%, 1/7; Group II: 0;P=0.33), ongoing pregnancy rate (Group I: 24%, 6/25;
Group II: 24%, 6/25; P= 1.0), or live births per cycle
(Group I: 24%, 6/25; Group II: 24%, 6/25; P=1.0) after an
IMSI. These results are summarised in Table 3.
Discussion
The goal of the ICSI and IMSI cycles is the transfer of
high-quality embryos because it is well known that the
implantation rates are directly related to the capacity of
the embryo to interact with a receptive endometrium.
Table 2 ICSI Procedure: Comparison between the Leukocytospermia (Group I) and Non-leukocytospermia
(Group II) groups
ICSI procedure
Group I Leukocytospermia Group II Non-leukocytospermia P value
Cycles 25 25
Leukocytes in semen (x106)
(mean± SD)
2.4 ± 1.7 (1–8) <1
Female age (years) 34.4 ± 3.8 34.5 ± 3.6 >0.99
Male age (years) 37.27 ± 5.0 36.7 ± 5.0 0.71
Aetiology (%) 0.41
Male 56% (14/25) 40% (10/25)
Idiopathic 16% (4/25) 16% (4/25)
Tuboperitoneal 12% (3/25) 8% (2/25)
Endometriosis 8% (2/25) 28% (7/25)
Tuboperitoneal + endometriosis 4% (1/25) 8% (2/25)
Male + tuboperitoneal 4% (1/25) ——
Semen parametersa (mean± SD)
Total sperm count (x106/mL) 43.2 ± 44.5 69.7 ± 51.5 0.06
Motility (% spermatozoa) 35.8 ± 17.8 50.7 ± 17.9 0.005
-rapid + slow progression 11.9 ± 12.3 11.2 ± 10.3 0.72
-non-progressive 50.4 ± 23.6 35.9 ± 13.6 0.0069
-immotile Morphology 0.06
-normal forms (%) 10.1 ± 0.8 17.9 ± 20.3 0.68
Vitality (%) 45.1 ± 17.5 48.8 ± 20.9 0.72
Metaphase II oocytes (n) 8.5 ± 4.2 7.3 ± 4.2 0.32
Fertilisation rate (%) 57.9 ± 30.2 61.9 ± 27.7 0.74
Embryos transfer (n) 2.2 ± 0.9 2.1 ± 1.0 0.60
Implantation rate (%) 12.3% (7/54) 13.5% (7/52) 0.93
Pregnancy/cycle (%) 24% (6/25) 24% (6/25) 1
Miscarriage (%) 0 0
Ongoing pregnancy/cycle (%) 24% (6/25) 24% (6/25) 1
Live birth/cycle (%) 24% (6/25) 24% (6/25) 1
a Semen quality parameters according to the World Health Organization [1].
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both gametes, it is important to assess the condition of
the male gametes by analysing seminal characteristics.
To evaluate male factors, the WHO manual established
that parameters such as sperm concentration, motility,
viability, morphology and leukocyte count should be
assessed [1]. In vitro studies have shown that a high level
of leukocytes can induce oxidative stress and alter sperm
parameters. However, the in vivo effects of leukocytes
are less clear. Although some authors have reported an
association between leukocytospermia and alterations in
sperm functions [4,5,7,9,33], a positive effect on the
morphology of leukocytes has also been described [3,35].
Additionally, some studies have reported that in infertile
individuals, leukocytes do not affect sperm function[36] and are associated with increased pregnancy rates
after assisted reproduction cycles compared to infertile
patients without leukocytospermia [17]. Thus, the sig-
nificance of leukocytospermia remains controversial, and
its relevance to male infertility has prevented questions
such as “Seminal leukocytes: passengers, terrorists or
good Samaritans?” [37] and “Semen leukocytes: friends
or foes?” [3] from being answered for almost two
decades.
With regard to leukocytospermia, the first issue to be
considered is that there is no consensus regarding the
threshold for the number of white blood cells in seminal
samples. Wolff [38] considered the value proposed by
the WHO to be too low, whereas Sharma et al. [39] and
Punab et al. [40] postulated that 1.106 leukocytes could
Table 3 IMSI Procedure: Comparison between the Leukocytospermia (Group I) and Non- leukocytospermia (Group II) groups
IMSI procedure
Group I Leukocytospermia Group II Non-leukocytospermia P value
Cycles 25 25
Leukocytes in semen (x106) (mean± SD) 4.8 ± 10.5 (1–50) <1
Female age (years) 34.8 ± 4.1 34.8 ± 3.8 >0.99
Male age (years) 37.4 ± 5.2 37.0 ± 6.0 0.84
Aetiology (%) 0.35
Male 36% (9/25) 44% (11/25)
Male age (years) 37.2 ± 5.0 36.7 ± 5.0 0.71
Idiopathic 20% (5/25) 28% (7/25)
Tuboperitoneal 24% (6/25) 8% (2/25)
Endometriosis 4% (1/25) 12% (3/25)
Male + endometriosis 8% (2/25) —
Male + tuboperitoneal 8% (2/25) 8% (2/25)
Semen parametersa (mean± SD)
Total sperm count (x106/mL) 41.0 ± 34.8 60.8 ± 43.6 0.068
Motility (% spermatozoa) 0.005
-rapid + slow progression 44.3 ± 21.8 58.6 ± 20.8 0.01
-non-progressive 10.5 ± 13.7 8.6 ± 8.3 0.82
-immotile 45.8 ± 21.0 31.4 ± 17.3 0.0048
Vitality (%) 43.1 ± 20.5 45.3 ± 18.7 0.72
MSOME b (%)
-normal spermatozoa 0.92 ± 1.43 1.35 ± 1.87 0.43
-spermatozoa with vacuoles occupying >50% of
the nuclear area
37.8 ± 20.2 34 ± 25.9 0.22
Metaphase II oocytes (n) 8.2 ±5.7 7.4 ± 4.9 0.65
Fertilisation rate (%) 67.6 ± 24.6 59.5 ± 28.1 0.36
Embryos transfer (n) 2.3 ± 0.8 2.6 ± 0.9 0.28
Implantation rate (%) 17.5% (10/57) 16.7% (9/54) 0.90
Pregnancy/cycle (%) 28% (7/25) 24% (6/25) 0.74
Miscarriage (%) 14.3% (1/7) 0 0.33
Ongoing pregnancy/cycle (%) 24% (6/25) 24% (6/25) 1
Live birth/cycle (%) 24% (6/25) 24% (6/25) 1
a Semen quality parameters according to the World Health Organization [1]; and b the motile sperm organelle morphology examination.
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seem to be due to the different end points evaluated in
these investigations [41]. Moreover, there seems to be a
considerable amount of spontaneous variation in white
blood cell counts in infertile men, which can reach a
spontaneous downward variation of up to 43% [42].
It has been determined that neutrophils and macro-
phages constitute 95% of seminal leukocytes, which may
promote male subfertility by damaging sperm via the
generation of ROS and the induction of apoptosis [43].
In semen samples associated with leukocytospermia,
DNA damage is promoted in a cascade-like manner,
which suggests that ROS play a major role in thesealterations [44]. Furthermore, an elevated leukocyte
count, in addition to supplying the main source of ROS
in the seminal plasma, may also be involved in retrovirus
transmission [45]. It is postulated that ROS may damage
the sperm membrane, reduce sperm motility and cap-
acity for fertilisation, and compromise sperm DNA [46].
However, the significance of the association between leu-
kocytospermia and ROS must be further clarified.
Although it seems clear that a high production of ROS
is associated with male infertility and that leukocytes are
the predominant source of ROS in sperm suspensions,
there is doubt as to whether these leukocytes infiltrate
the epididymis and are thus responsible for the impaired
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have reported that in men with normal sperm concen-
trations, sperm dysfunction may occur as the result of
the cytotoxic effects of nitric oxide (NO). NO is a free
radical that is believed to be a mediator of sperm func-
tion [49], and leukocytospermia is likely responsible for
the increase in NO concentrations. Nevertheless, when
patients with leukocytospermia show increased activity
of NO synthase with normal levels of NO, sperm motil-
ity and viability are not compromised [48].
Another point for consideration is whether a leukocy-
tospermic sample is of sufficiently good quality based on
all of the other parameters evaluated. Erenpreiss et al.
[44] reported that alterations of DNA integrity are sig-
nificant only between semen samples of very good and
very poor quality, and they stress that the concentration
and motility parameters of normal semen may be resist-
ant to the DNA damage associated with leukocytosper-
mia. Even when considering that leukocytospermia is
associated to the production of ROS and impairs semen
function, it remains unclear whether this seminal dys-
function would have any impact on ART outcomes. Al-
though lower fertilisation and cleavage rates have been
reported in the presence of leukocytospermia [15,50], a
more recent investigation reported that the ICSI out-
comes were impaired when seminal samples associated
with this condition were employed, even though there
was a trend for an association with male infertility
[16,17]. Furthermore, it was demonstrated that fertile
semen donors could also have leukocytospermia (≥106/
mL) [51]. Another study showed a negative effect of
ROS on conventional IVF cycles, which was not
observed for ICSI cycles [52]. Alternatively, the impact
of ROS in ART cycles may be more complex than simply
their presence or absence in the semen samples [16,53],
given that ROS seem to have distinct effects on semen.
Therefore, ROS may additionally exert a beneficial influ-
ence in the process of capacitation [54-57].
The results of our investigation demonstrated a trend
towards association between leukocytospermia with im-
portant semen parameters, including concentration and
motility, which were reduced in comparison with control
patients. This finding is in contrast with the observations
of Lackner et al. [16], who did not find any influence of
leukocytes on sperm motility. However, our observations
are in agreement with other previous reports. Fedder [4]
observed an association between high concentrations of
certain white blood cell products and the inhibition of
experimentally measured sperm functions (e.g., motility).
Arata de Bellabarba et al. [5] reported that leukocytos-
permia occurs frequently in infertile patients and that it
is associated with poor semen quality parameters. Saleh
et al. [7] found that leukocytospermia was associated
with a significant decrease in sperm motility. Aziz et al.[33] reported that the leukocytic concentration in semen
was significantly and negatively correlated with the mo-
tile sperm percentage but not with sperm concentration.
The results of Moskovtsev et al. [9] indicated that leuko-
cytospermia has a significant negative effect on the
standard semen parameters of concentration, motility,
and morphology. In addition, Barraud-Lange et al. [17]
analysed 1955 semen samples and found a significant
correlation between the amount of leukocytes and the
deterioration of semen parameters (e.g., sperm count,
total sperm number and motility). Thus, our data em-
phasise the correlation between leukocytospermia and
abnormal semen quality. Conversely, it should be noted
that the correlation between the morphology of the
semen and the presence of leukocytes was a contradict-
ory point among the previous studies. The existence of a
leukocyte function in the elimination of abnormal
spermatozoa from ejaculated semen has already been
analysed [3]. In our study, although the average numbers
of sperm with a normal form were always lower in the
groups with leukocytospermia, there was no significant
difference from the samples without leukocytospermia.
This finding is consistent with other previously pub-
lished studies [17].
With regard to the fertilisation, implantation, miscar-
riage, ongoing pregnancy and live birth rates, we did not
observe any statistically significant differences between
the groups with or without an increased number of leu-
kocytes in the seminal fluid. Our data are in agreement
with the report of Lackner et al. [16], who found that
leukocytospermia might not have a negative effect on
the outcomes of IVF/ICSI cycles. We can postulate that
the techniques of ICSI and IMSI are capable of bypass-
ing the negative effects of leukocytospermia and the
consequences of ROS on the sperm quality. Moreover,
our group routinely performs IMSI to avoid insemin-
ation of oocytes with sperm that have large nuclear
vacuoles (LNV; spermatozoa with vacuoles occupying
>50% of the nuclear area), which reflects the presence
of abnormal chromatin packaging, thereby facilitating
sperm DNA damage [58]. The selection of sperm with-
out LNV may prevent the injection of sperm with DNA
fragmentation, which, according to Fariello et al. [10], is
likely to occur in samples with leukocytospermia. How-
ever, the possibility that the presence of leukocytes did
not have a deleterious effect on ART outcomes cannot
be eliminated. Barraud-Lange et al. [17] in fact proposed
that leukocytospermia is protective in vivo and that it is
associated with normal or improved IVF and ICSI
results when compared with non-leukocytic patients
with infertility. In a study analysing 3508 IVF/ICSI
cycles, the fertilisation rate, cleavage rate, clinical preg-
nancy rate, gestational age, and mean infant weight were
significantly improved when seminal leukocytes were
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http://www.rbej.com/content/10/1/44present, regardless of the technique used. The only nega-
tive side effects associated with a high level of seminal
leukocytes (≥106/mL) were an elevated rate of early
pregnancy loss (from 26.6% to 40.5%) and a 3-fold in-
crease in the percentage of ectopic pregnancies. Thus,
further trials with larger sample sizes will be helpful in
determining the in vivo role of seminal leukocytes.
A limitation of our study is the low number of sperm
samples and cycles that were analysed. The present
study failed to show any statistically significant differ-
ences in the clinical outcomes, including clinical preg-
nancy, ongoing pregnancy and live birth rates. This
observation may be related to the small cumulative sam-
ple size (i.e., insufficient power). With respect to ongoing
pregnancy rates, based on the results obtained with the
leukocytospermia and non-leukocytospermia groups in
ICSI cycles (24%, 6/25 and 24%, 6/25, respectively) and
in IMSI cycles (24%, 6/25 and 24%, 6/25, respectively),
the ability to detect a difference of 5% with a power of
80% and to reach definitive conclusions would require
more than 4000 cycles. Thus, future controlled trials
that provide more information on clinical parameters
will help to clarify the reliability of these results. Alterna-
tively, it should be emphasised that other published
studies reported data from small samples of leukocytos-
permic men. Lackner et al. [16] evaluated 20 men with
leukocytospermia in groups of 75 individuals. During a
7-year follow-up in an ART programme, a study
reported a concentration of ≥106/mL leukocytes in the
semen of only 73 men out of a total of 1955 who were
analysed [17]. Therefore, despite our small study popula-
tion, we believe that our work can contribute to the
understanding of leukocytospermia.
In conclusion, the results of this investigation indicate
that leukocytospermia may not have a negative effect on
the outcomes of ICSI and IMSI cycles. Nevertheless, it is
necessary to more precisely determine the effects, if any,
of seminal leukocytes on the fertilisation and implant-
ation processes and to establish a more reliable
leukocyte threshold that could eventually demonstrate
negative influences on the ART procedures.Competing interests
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